Congratulations! FAB Helps the Worlds First Subcutaneous PD-L1 Envelopimab Injection Approved in China
On 25 November 2021, 3D Medicines (Beijing) Co., Ltd. (3DMed), Alphamab Oncology, and Simcere Pharmaceutical Group Limited (Simcere) jointly announced that Envafolimab (KN035), the...
2022-02-08
2121
MORE >>